If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Tobi Approved In Canada And Argentina For CF SEATTLE, WA -- Feb. 17, 1999 -- PathoGenesis Corp.’s Tobi(R) (tobramycin solution for inhalation) has received marketing clearance from regulatory authorities in Canada and Argentina for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa infections. Some 3,000 Canadians with cystic fibrosis are treated primarily at 36 cystic fibrosis specialist centres. In Argentina, about 700 patients also are treated at centralised cystic fibrosis centres. Tobi is designed for these patients to take at home in repeated cycles of 28 days on drug, 28 days off drug. Each ready-to-use ampule of Tobi contains 300 milligrams of tobramycin in a 5 millilitre solution. Tobi is aerosolised and administered using a Pari LC Plus(TM) reusable nebulizer and DeVilbiss PulmoAide(R) air compressor. It is inhaled twice daily and requires about 15 minutes each time. Cystic fibrosis is characterised by the production of unusually thick, sticky mucus that typically blocks the airways of the lungs. Consistent production of mucus prevents clearance of bacteria, allowing them to colonise and multiply. As a result, chronic infection and inflammation occur, causing people with cystic fibrosis to experience persistent coughing, sputum expectoration and wheezing. This inflammation and infection lead to lung damage and destruction, and ultimately, death. CF also can affect other areas of the body, including the pancreas and sweat glands. Related Links: Doctor's Guide to Cystic Fibrosis, Tobi, PathoGenesis Corp.
|
